Clinical Trial Update: Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating ablation in combination with lenvatinib and anti-PD-1 antibodies for hepatocellular carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• anti-PD-1 antibodies (PD-1 inhibitor)

Snippet

Sponsor: Hua Li | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING